Home PEx News and Tech Local and Foreign Issues

Which company's vaccine will you choose?

Government say that they are talking with several vaccine producers, including Pfizer, Sinovac, AstraZeneca and so on. It is estimated that we can get first batch of vaccines in May or June. When it's time to vaccinate, which company do you prefer?
«1

Comments

  • PalmongTulsaPalmongTulsa PEx Rookie ⭐
    How close is the Philippines to getting which COVID-19 vaccines? 
    https://www.philstar.com/headlines/2020/12/16/2063687/how-close-philippines-getting-which-covid-19-vaccines

     Lawmakers have allocated P72.5 billion in funding as the government plans to inoculate 24 million against the novel coronavirus in 2021. But as the picture on the health crisis continues to unfold, concerns grow that the Philippines may be lagging behind in securing supplies.

    A global tracker has estimated that 9.6 billion doses have already been reserved — 3.9 billion of which will go to high-income countries even with the vaccine still not out in the market.

    At home, vaccine czar Carlito Galvez Jr. has said that 80% of the vaccines have been taken by rich countries. The Philippines government is seen to sign most procurement deals by January, or around a year since the first confirmed case in the Philippines.

    Officials have repeatedly denied that the administration was late in seeking access to the vaccines. Talks with drug manufacturers began as early as August and President Rodrigo Duterte approved advance payment for the vaccines by November.

    He had earlier rejected the idea, saying developers from the West were trying to make a profit by asking for payment in advance.

    Galvez has said that they saw the urgency and that the country is "not in the tail-end," as he repeated that procurement laws are restrictive.

    "His guidance is to look for ways na nandoon tayo, nauuna tayo sa pag-roll out. Talagang napakahirap..kasi 'yung R.A. 9184 does not allow advance commitment and only with approval of the president," he said..

    How close are we to getting vaccines?

    The world is ending the tumultuous year in a pandemic with significant progress on potential coronavirus vaccine candidates. And with it comes the race for countries, including the Philippines, to secure enough doses for their people. But what has been our progress exactly?

    As of December 15, here are some of the candidate vaccines that could see their way to the Philippines by 2021.

    AstraZeneca

    The country secured 2.6 million doses from the British-Swedish pharmaceutical in end-November and is seen to arrive by the middle of next year.

    This deal was sealed through the efforts of the private sector as firms chipped in P600 million to buy them. With an average efficacy of 70%, the vaccine costs $10 or P500 for two doses and would be donated to the government for the health department to distribute.

    The private sector purchase is separate from the 20 million doses that the government is looking to buy from the same drugmaker using public funds.

    AstraZeneca last week pulled out of joining clinical trials in the Philippines, as it said it now has enough data on the vaccine.
    This leaves Sinovac Biotech ltd., Sichuan Clover Biopharmaceuticals, Gamaleya Research Center as well as Johnson and Johnson’s Janssen in the process of getting approvals for clinical trials in the country.                         
  • PalmongTulsaPalmongTulsa PEx Rookie ⭐

    Sinovac

    The Chinese-developed vaccine has been in the spotlight in recent days as one public health expert raised concerns that government is securing 25 million doses despite it being the second most expensive among candidates and doubts of over safety.

    At two doses, the Sinovac is seen at P3,600 per rough estimates reported by Sen. Sonny Angara, chair of the Senate finance commitee, in deliberations on the proposed national budget for 2021.

    Malacañang has since defended this, saying it is the only choice that could arrive in the country by the first quarter of 2021.

    The drugmaker has also not escaped controversy as allegations surface that Sinovac's CEO bribed Chinese regulators to fast track the approval of its vaccines for SARS in 2003 and the swine flu in 2009. Health Secretary Francisco Duque III has said they are aware of the report and will look into the claims

    Sinovac is also among those seeking approval from authorities to hold a clinical trial here seen by late December or early January 2021 after passing technical review. 

    Gamaleya

    Russia's Sputnik V was the first in the world to secure approval from its own country back in August, with Gamaleya Research Institute claiming 95% efficacy per another interim analysis of its clinical trial data. 

    Galvez has said Sputnik V could also be in the country by the first quarter of 2021, but that there may be "more confidence" in China's Sinovac as other countries have already received their doses. 

    In an update on December 4, Dr. Nina Gloriani, who heads DOST's vaccine experts panel, said approval for Gamaleya has been deferred as it has yet to turn in additional documents required. 

    "We want the scientific interim data," she said. "We cannot rely on what they published on the internet." 

    Clover

    Sichuan Clover Biopharmaceuticals hurdled the Vaccine Expert Panel's review on November 24, nearly a month since it submitted its application in end-October. Its application has since been forwarded to the Food and Drug Administration, with trials seen to start by early 2021 if not before yearend. 

    "Dapat two weeks lang sa amin (VEP) eh tumagal dahil maraming tanong kaya nag-stop 'yung clock," Dr. Nina Gloriani of the government's VEP said, "pero FDA should be able to act on it in two to three weeks."

    Sichuan Colver is the second drugmaker from China to seek approval to hold clinical trials in the Philippines. The vaccine comes in two doses, but officials have yet to disclose its price. 

  • PalmongTulsaPalmongTulsa PEx Rookie ⭐

    Janssen

    The Belgian-led Janssen Pharmaceutica of Johnson & Johnson secured the VEP's approval on December 11, bringing it closer to being able to hold clinical trials in the country.

    In contrast to others, the vaccine is only taken in a single dose. In October, developers momentarily halted its Phase 3 trial in the US after an "unexplained illness" in one of its participants. 

    Janssen in October 23 announced that it was resuming the said trials after reporting that no clear cause came out from its evaluation on the incident. "Based on the information gathered to date and the input of independent experts, the company has found no evidence that the vaccine candidate caused the event," it said in a release.

    Pfizer 

    Health officials have said that the American drugmaker will not hold trials in the Philippines as the company said "they are well advanced" at their Phase 3 stage. 

    Undersecretary Maria Rosario Vergeire said most of the talks with Pfizer had focused on the pre-order of its potential vaccines. 

    Manila's envoy to Washington Jose Manuel Romualdez said last month that vaccines from the US could arrive in the Philippines early 2021 "at the latest," while Angara has reported too that the cost of Pfizer is at P2,400 for the two doses required per individual, with an efficacy rate of 90%.

    The US FDA has allowed the emergency use of the Pfizer vaccine in the US, which has the most infections at over 16.6 million and deaths of more than 300,000.

    Moderna 

    This US-made vaccine is not applying for clinical trials in the Philippines. 

    It has a 94% efficacy and is taken in two doses. At a price range of P3,900 to P4,500, it is the most expensive vaccine being eyed by the country yet.

    Health officials have said that the drugmaker is keen to provide doses here but likely only by the second quarter of 2021.

    Moderna is expected to be cleared for emergency use in the US, as officials there report that the vaccine is "highly effective."

    Novavax

    Another possible COVID-19 vaccine from the US could make it to the Philippines through a local collaboration for distribution. 

    Faberco Life Sciences Inc., a partner of Serum Institute of India Pvt. Ltd., said in November that it is on standby to communicate with the government for a partnership.

    Luningning Villa, Faberco's medical director, said that SII is eyeing to produce over a billion doses of Novavax, which is being evaluated in different countries.

    Figures from Sen. Angara showed that Novavax could be the cheapest vaccine at only P366 in two doses and could actually cover the country's over 108 million population. 

  • PalmongTulsaPalmongTulsa PEx Rookie ⭐

    Sinopharm

    The Chinese pharmaceutical firm in October backed out of its application to hold clinical trials in the Philippines.

    Science and Technology Secretary Fortunato dela Peña, in announcing the development, said Sinopharm had a "change of mind" but has said that they are still interested in rolling out supplies. 

    United Arab Emirates officials this month approved the use of the Chinese firm's COVID-19 vaccine, saying it was 86% effective. The vaccine, which comes in two doses, has been under Phase 3 trials in the UAE since July and secured emergency use for medical workers in September. 

    Vaccine transparency

    Apart from questions on securing doses, concerns still loom among senators on the vaccination program in general, with the chamber agreeing to convene as a Committee of the Whole for a probe into the matter.

    "The fact that senators are pretty much in the dark as to the game plan does not bode well for transparency and accountability in the vaccine rollout," said Sen. Francis Pangilinan. "Transparency in the process is key if there is to be public trust in a rollout and without the public's trust, a program of this magnitude will not succeed."

    An SWS survey in November showed that 66% of Filipinos were willing to get vaccinated for COVID-19, while 31% said they were not. Vaccination efforts in the country over the past years have been strained in large part due to fears from a botched dengue vaccination program in 2017, despite no established links of deaths resulting from the inoculation of Dengvaxia.

    Health Secretary Duque has vowed to boost public confidence in the supposed COVID-19 vaccines, but Rep. Janette Garin (Iloilo), who was health secretary when the Dengvaxia program was carried out, chided him for failing to correct false information on the vaccine.

    "He keeps on mouthing improving vaccine confidence while at the same time failing to directly correct the wrong information that dengue vaccine kills,"  Garin, who is facing raps over the Dengvaxia mess, said in a statement. "By having conflicting statements, Duque has been a big contributor to our decline in vaccine confidence."

  • PalmongTulsaPalmongTulsa PEx Rookie ⭐

    Philippines can secure up to 25 million doses of Moderna, Arcturus vaccines-ambassador

    https://www.reuters.com/article/us-health-coronavirus-philippines/philippines-can-secure-up-to-25-million-doses-of-moderna-arcturus-vaccines-ambassador-idUSKBN28S0CR

     The Philippines will be able to secure between four to 25 million doses of COVID-19 vaccines from Moderna Inc and Arcturus Therapeutics Holdings Inc, the Southeast Asia country’s ambassador to Washington said on Friday.

    The U.S. companies were ready to supply the vaccines from the third quarter of 2021, Philippine Ambassador Jose Manuel Romualdez said in a statement, if his government found their proposals acceptable.

    “We are hoping our government will consider the promising candidates of Moderna and Arcturus for inclusion in our country’s pool of anti-COVID-19 vaccines,” Romualdez said.

    The U.S. Food and Drug Administration is expected to grant Moderna emergency use authorization soon. Arcturus expects to start distributing its vaccine in the first quarter of next year after early stage trials showed promising results.

    Moderna and Arcturus did not immediately respond to a request for comment.

    At a news conference, Philippine Health Ministry Undersecretary Maria Rosario Vergeire welcomed signs of progress in the negotiations but said each vaccine candidate would need to get regulatory approval to ensure safety and efficacy.

    The Philippines plans to buy 25 million doses of a vaccine supplied by China’s Sinovac Biotech for delivery by March. In addition, the private sector agreed last month to acquire 2.6 million shots of a vaccine developed by AstraZeneca in the nation’s first supply deal for a coronavirus vaccine.

    The Southeast Asian nation had missed out on an opportunity to buy 10 million doses of Pfizer’s vaccine for delivery in January, Romualdez said.

    With 454,447 infections and 8,850 deaths, the Philippines has reported the second-highest number of COVID-19 infections and casualties in Southeast Asia, next to Indonesia.

  • PalmongTulsaPalmongTulsa PEx Rookie ⭐

    PH taps global vaccine pool of 2 billion doses

    https://globalnation.inquirer.net/192809/ph-taps-global-vaccine-pool-of-2-billion-doses

    As officials bickered over the government’s supposed failure to get an initial shipment of COVID-19 vaccines in January, the World Health Organization (WHO) on Saturday announced that the global Covax Facility had secured 2 billion doses for 190 countries, including the Philippines.

    WHO Director General Tedros Adhanom Ghebreyesus said countries that had signed up to the Covax Facility would be able to obtain the vaccines in the first half of 2021 to protect those at high risk of infection, like medical frontliners.

    Health Undersecretary Maria Rosario Vergeire confirmed that the Philippines was among the 85 countries which had already submitted their requests to Covax. She said, however, that the Department of Health could not yet disclose details of the country’s request.

    Covax is the vaccine arm of the Access to COVID-19 Tools Accelerator, which aims to speed up the development, production and “equitable access” to coronavirus tests, COVID-19 treatments and vaccines.

    Among the manufacturers that have committed to supply vaccines to Covax are AstraZeneca (170 million doses), Johnson & Johnson (200 million doses) and the Serum Institute of India (200 million doses, plus possibly 900 million more).

    ‘End in sight’

    Tedros said that even with this “milestone in global health,” people should remember that vaccines only serve to “complement, not replace, the existing effective tools for suppressing transmission and saving lives.”

    He said “the end of the pandemic is in sight” but people should not let their guard down.

    “We’re all responsible for taking the measures to keep ourselves and each other safe, including during this holiday season. With [this] news, the light at the end of the tunnel has grown a little bit brighter, but we’re not there yet. And we will only get there together,” he said.

    Coleading the WHO in the facility are the Coalition for Epidemic Preparedness Innovations and Gavi, or the Vaccine Alliance, which is a public-private global health partnership whose goal is to increase access to immunization by poor countries.

    The Philippines joined Covax in July and was among the 92 countries that would be supported by the Advance Market Commitment (AMC) funding mechanism, which has so far raised $2 billion. AMC ensures that the ability to pay will not hinder low- and middle-income countries from accessing the vaccines.

    Equitable distribution

    WHO chief scientist Dr. Soumya Swaminathan said a “fair allocation mechanism” was developed to make sure the vaccines are equitably distributed.

    She told a virtual briefing on Saturday that vaccines would be distributed to countries “by tranches based on the percentage of their population.”

    Swaminathan said there was an understanding that most countries would prioritize their health and other front-line workers, who account for about 2 percent to 3 percent of the population.

    According to Gavi CEO Seth Berkley, deliveries are expected to start in the first quarter of 2021.

    Berkley stressed that this would depend on the availability of the vaccine, the approvals for these vaccines and the readiness of countries to receive them.

    With Covax securing the initial doses, Swaminathan said governments should now ensure that their communities are well-informed about how the vaccines would be rolled out, making sure the cold chain, supply chain and data systems were in place, and that regulatory approvals “happen rapidly.”


  • Herr_StarrHerr_Starr PEx Influencer ⭐⭐⭐
    Pfizer and Moderna have gotten approvals across most Developed Countries. Pfizer is getting a lot of attention as numerous key figures have been publicly vaccinated (Biden, Pence, Etc). 

    Most smart countries have already locked in supply. 

    Not enough information for vaccines from China and Russia. 
  • PalmongTulsaPalmongTulsa PEx Rookie ⭐
    Pfizer and Moderna have gotten approvals across most Developed Countries. Pfizer is getting a lot of attention as numerous key figures have been publicly vaccinated (Biden, Pence, Etc). 

    Most smart countries have already locked in supply. 

    Not enough information for vaccines from China and Russia. 
    agree with you. I think I also prefer Pfizer.
    But I heard that China has vaccinated millions of people. 
    Anyway, I will definitely choose a vaccine that developed by a big country. No India Vaccine!
  • PalmongTulsaPalmongTulsa PEx Rookie ⭐

    Philippines to get 30mln doses of Novavax COVID-19 vaccine

    https://www.arabnews.com/node/1780466/world
    The Philippines expects to receive 30 million doses of Novavax Inc’s COVID-19 vaccine by July next year, its foreign minister said on Monday, boosting the country’s effort to secure supplies to inoculate more than 100 million people.
    Despite consultations with numerous vaccine makers, the Philippines has so far signed only one supply deal, with the help of its private sector, to acquire 2.6 million shots of a vaccine developed by AstraZeneca.
    It plans to buy 25 million doses of a vaccine from China’s Sinovac Biotech for delivery by March and aims to secure between four and 25 million doses of vaccines from Moderna and Arcturus Therapeutics Holdings Inc.
    “Thirty million dosages of the Indian-made Novavax vaccines are assured possibly with no cash advance. It will be available by July 2021,” Foreign Affairs Secretary Teodoro Locsin said in an interview with CNN Philippines.
    He said the information came from Serum Institute of India, the world’s largest vaccine producer, and that the terms of the supply deal may be signed before the end of the year.
    There was no immediate comment from the institute, which in August entered a supply and license agreement with Novavax Inc. for the development and commercialization of its COVID-19 vaccine candidate.
    Talks with Moderna, which has been granted emergency use authorization by the US Food and Drug Administration, will begin next week, Locsin said.
    With 459,789 infections and 8,947 deaths, the Philippines has recorded the second-highest number of COVID-19 infections and casualties in Southeast Asia after Indonesia.
  • PalmongTulsaPalmongTulsa PEx Rookie ⭐

    Locsin, Galvez: PH to receive 30M COVID-19 vaccine doses from Novavax

    https://cnnphilippines.com/news/2020/12/22/Locsin--Galvez--PH-to-receive-30M-COVID-19-vaccine-doses-from-Novovax.html

    Two high-ranking government officials confirmed on Monday the Philippines will receive 30 million doses of Novavax's COVID-19 vaccine.

    Foreign Affairs Secretary Teddy Boy Locsin Jr. said the delivery of the vaccines, made at the Serum Institute of India, will arrive in the country by July 2021.

    "The good thing though, is that remember: This is not a rumor. This is based on a press release made by Serum Institute of India – the giant manufacturer," Locsin told CNN Philippines' Pinky Webb.

    COVID-19 National Task Force Chief Implementer Carlito Galvez Jr. also relayed the development to President Rodrigo Duterte, saying Serum did not request anymore for a cash advance in the Philippine government's purchase of Novavax vaccine doses.

    Galvez added the Novavax vaccine makers were struck by Duterte's speech during the United Nations General Assembly, where he appealed for equal access of safe and effective COVID-19 vaccines to all countries.

    "He (representative of Serum Institute of India) will comply with your directive that no cash advance will be placed," Galvez said during the weekly Inter-Agency Task Force on the Management of Emerging Infectious Diseases meeting.

    Galvez said they will talk with Serum Institute of India representatives on Dec. 23.

    He also reported to Duterte they may sign a contract next week with British pharmaceutical company AstraZeneca, which will supply 20 million doses to the country. Around half of those doses are allocated to local government units and the rest are for the private sector.

    The country has so far formally secured 2.6 million doses of AstraZeneca's vaccine due to arrive in the second quarter of 2021, coming from a ₱600-million donation from over 30 private companies.

    "If these deals will be signed, we will have around 60 million doses for the second and third quarter of 2021," Galvez said.

    Locsin also said the Philippines will start its negotiations for a potential COVID-19 vaccine supply agreement with American biotechnology company Moderna "on or before" Dec. 30. Philippine Ambassador to the United States Babe Romualdez confirmed Moderna's willingness to supply the Philippines with four million to 25 million doses by the third quarter of 2021.

  • Herr_StarrHerr_Starr PEx Influencer ⭐⭐⭐
    Pfizer and Moderna have gotten approvals across most Developed Countries. Pfizer is getting a lot of attention as numerous key figures have been publicly vaccinated (Biden, Pence, Etc). 

    Most smart countries have already locked in supply. 

    Not enough information for vaccines from China and Russia. 
    agree with you. I think I also prefer Pfizer.
    But I heard that China has vaccinated millions of people. 
    Anyway, I will definitely choose a vaccine that developed by a big country. No India Vaccine!
    I'll wait for the Lancet or the NEJM peer reviewed studies on China's and Russia's vaccine efforts before commenting further on these treatments. 

    As for India, the World's largest vaccine manufacturer is an Indian Company, a lot of the first tier solutions will wind up being outsourced to India. As long as it is peer reviewed, I would have no qualms taking such a treatment ;)
  • PalmongTulsaPalmongTulsa PEx Rookie ⭐
    Pfizer and Moderna have gotten approvals across most Developed Countries. Pfizer is getting a lot of attention as numerous key figures have been publicly vaccinated (Biden, Pence, Etc). 

    Most smart countries have already locked in supply. 

    Not enough information for vaccines from China and Russia. 
    agree with you. I think I also prefer Pfizer.
    But I heard that China has vaccinated millions of people. 
    Anyway, I will definitely choose a vaccine that developed by a big country. No India Vaccine!
    I'll wait for the Lancet or the NEJM peer reviewed studies on China's and Russia's vaccine efforts before commenting further on these treatments. 

    As for India, the World's largest vaccine manufacturer is an Indian Company, a lot of the first tier solutions will wind up being outsourced to India. As long as it is peer reviewed, I would have no qualms taking such a treatment ;)
    it makes sense. I am also waiting.
  • PalmongTulsaPalmongTulsa PEx Rookie ⭐
    Security team for Philippines' Duterte gets unauthorised Chinese Covid-19 vaccine

    https://economictimes.indiatimes.com/news/international/world-news/security-team-for-philippines-duterte-gets-unauthorised-chinese-covid-19-vaccine/articleshow/79992940.cms

    Members of Philippine President Rodrigo Duterte's security team have received a Chinese-made coronavirus vaccine, officials said Monday -- the first people in the country to be officially immunised despite no regulatory approval.

    The Philippines is in talks with several pharmaceutical firms, including Britain's AstraZeneca NSE 3.21 %, US company Pfizer and China's Sinopharm, to secure 60 million doses for a vaccination drive starting as early as the second quarter of 2021.

    No vaccine has been approved by the country's Food and Drug Administration (FDA), which is required before it can be rolled out across the country of 110 million people.

    But the Presidential Security Group (PSG) -- which is tasked with protecting Duterte -- said some of its personnel have already been inoculated.

    "The PSG administered Covid-19 vaccine to its personnel performing close-in security operations to the President," unit chief Brigadier General Jesus Durante said in a statement, without specifying how many got the drug. 

    Asked if Duterte had been immunised, Durante said the president was still waiting "for the perfect or appropriate vaccine".


  • Could be scared. Who won't be, when there are reports of adverse reactions to some of those vaccinated no matter who provides it?
  • Herr_StarrHerr_Starr PEx Influencer ⭐⭐⭐
    Could be scared. Who won't be, when there are reports of adverse reactions to some of those vaccinated no matter who provides it?
    If you don't have a history of significant allergic reactions, there is nothing to worry about. 


  • PalmongTulsaPalmongTulsa PEx Rookie ⭐
    Could be scared. Who won't be, when there are reports of adverse reactions to some of those vaccinated no matter who provides it?
    don't worry so much. the possibility is sooooo tiny! we will all be fine. just need to wait for a safe and efficient vaccine!
  • PalmongTulsaPalmongTulsa PEx Rookie ⭐

    Philippines approves trials for Janssen’s COVID-19 vaccine

    https://www.rappler.com/nation/philippines-approves-trials-janssen-covid-19-vaccine

    The Philippines has approved the application of Janssen Pharmaceutica to conduct Phase 3 clinical trials for its COVID-19 vaccine in the country, the Food and Drug Administration (FDA) announced on Tuesday, December 29. 

    “Yesterday we already approved one, this is the clinical trial application of Janssen. This has been given the go-signal by FDA,” FDA Director General Enrique Domingo said in a press briefing.

    With the regulatory aspect of its application done, the FDA chief said Janssen’s trials could begin in the “next few weeks” after the Department of Science and Technology assigns areas to be included and recruits volunteers. 

    The Janssen Pharmaceutica trials mark the first late stage trials for a COVID-19 vaccine in the Philippines. The company is one of 3 firms that applied for trials in the country, with China’s Sinovac and Clover Biopharmaceuticals still undergoing regulatory review. 

    Domingo welcomed the start of Janssen’s trials, saying these would allow the Philippines to contribute to worldwide knowledge on the development of a COVID-19 vaccine. The trials will also help scientists and medical experts confirm the effects of the vaccine on Filipinos. 

    Janssen, the pharmaceutical firm of Johnson & Johnson, is developing a vaccine using a  “non-replicating viral vector” called Adenovirus 26, which  has been genetically engineered so it can still invade cells but can’t replicate and cause disease. The company used the same method to develop vaccines for Ebola and other diseases. 

    Advertisement

    Unlike most other candidates, Janssen’s vaccine utilizes a single dose. Despite this, the company said it would use some Phase 3 trials to study the effects of two doses given 56 days apart. 

    Its vaccine can also be stored in standard refrigerated facilities, making the prospect of distributing and administering vaccines easier for lower income countries like the Philippines.

  • PalmongTulsaPalmongTulsa PEx Rookie ⭐

    Filipina nurse in US describes experience after getting COVID-19 vaccine

    https://cnnphilippines.com/lifestyle/2020/12/26/Filipina-nurse-US-COVID-19-vaccination-.html

    Kat Bermudez, a Filipina nurse based in the United States, was among the first people in the US to receive the coronavirus vaccine developed by drug makers Pfizer and BioNTech.

    Bermudez, who works at the Stanford Hospital in California, said she did not have any adverse reaction to the new vaccine, except for a temporary arm pain, which she noted was a common side effect of inoculation. She received her first dose last Monday and is set to get her second shot on Jan. 12.

    “So far, I didn't have any issues with it except for that pain in my arm that lasted for about two days,” the nurse told CNN Philippines’ Newsroom Weekend on Saturday.

    “But I had COVID in November that is why I thought maybe that is part of the reason why I did not have as [many] side effects,” she added.

    Bermudez also said none of her colleagues experienced side effects after their COVID-19 vaccination, adding they “all did fine.”

    But she underscored the importance of being informed about the coronavirus vaccine, including its safety and risks before deciding to get inoculated, saying there is still a lot to be known about this new product.

    Earlier this month, at least three health care workers in Alaska had an allergic reaction after receiving a dose of the new Pfizer and BioNTech's vaccine, CNN has reported. All of them have reportedly recovered from the allergies.

    More than one million people have received their first shot of a COVID-19 vaccine in the US. 

    The US Centers for Disease Control and Prevention's Advisory Committee for Immunization Practices recommended that health care workers and residents of long-term care facilities get the vaccines first.

    The vaccine produced jointly by Pfizer and BioNTech was the first to receive an emergency use authorization in the US, followed by Moderna. 

Sign In or Register to comment.